WASHINGTON (AP) -- Type 2 diabetics got a new option to help control their blood sugar Friday, a drug derived from the saliva of the Gila monster -- but one that must be injected twice a day.
The Food and Drug Administration approved Byetta, known chemically as exenatide, the first in a new class of medications for Type 2 diabetes -- but for now, it's supposed to be used together with older diabetes drugs, not alone.
Makers Amylin Pharmaceuticals and Eli Lilly & Co. said the prescription drug would begin selling by June 1, but wouldn't provide a price.
Some 18 million Americans have diabetes, the vast majority the Type 2 form, in which the body loses the ability to turn blood sugar into energy because it either doesn't produce enough insulin or doesn't use it correctly. It is closely associated with obesity.
When diet and exercise aren't enough to control Type 2 diabetes, patients can try certain oral medications to lower blood sugar. The most common, drugs called sulfonylureas, spur the body to produce more insulin.
When those drugs fail, adding Byetta to them offers patients a new option to try before resorting to injections of insulin.
Byetta is the first so-called "incretin mimetic," meaning it mimics action of a hormone called GLP-1 that's secreted by the gut to spur insulin production after a meal -- but only when blood sugar is high.
That's important, noted FDA metabolic drugs chief Dr. David Orloff, because other diabetes drugs spur insulin secretion even if blood sugar already is low, leading to the risk of hypoglycemia.
Byetta is a synthetic version of a protein found in the saliva of the Gila monster that works similarly to the human GLP-1.
In studies, Byetta was given in addition to sulfonylureas, another common diabetes drug called metformin, or a combination of the older treatments.
Adding Byetta triggered about a 1 percent drop in patients' A1C levels, an important measurement of blood-sugar averages, Orloff said. That's consistent with blood-sugar lowering caused by other diabetes drugs, he said.
Read The Full Article : Here
Credit To Author.
Disclaimer
This website contains copyrighted news material - the use of which has
not always been specifically authorized by the copyright owner. We believe
that our use of such material for nonprofit educational purposes (and other
related purposes) constitutes a 'fair use' of the copyrighted material as
provided for in the US Copyright Law at Title 17 U.S.C. Section 107. If you
wish to use this copyrighted material for purposes of your own that go
beyond 'fair use', you must obtain permission from the copyright owner. If
for any reason you believe that our use of your material on this site does
not fall within the fair use guidelines, please immediately notify The Black
Vault so that we can promptly address the matter.
Sincerely,
John Greenewald, Jr.
The Black Vault Headquarters
http://www.blackvault.com
| 
Online Stats: 
